logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Bintrafusp alfa for locally advanced or metastatic biliary tract cancer – second-line

< Back

Bintrafusp alfa for locally advanced or metastatic biliary tract cancer – second-line

Drugs

Cancer and Palliative Care

September 2020


Biliary tract cancer (BTC) is a rare type of cancer that affects bile ducts, which are tubes that link the gallbladder, liver and pancreas together. Bile is produced in the gallbladder and is transported to the small intestine to aid the digestion of fatty foods. Advanced or metastatic biliary tract cancer is cancer that has grown a considerable amount and/or spread to other areas of the body and is incurable. Chemotherapy using gemcitabine and cisplatin is standard of care for first-line therapy in patients whose cancer is inoperable, and there are very limited second-line therapies for patients who have received platinum-based chemotherapy but where the cancer has not responded or relapsed.

Bintrafusp alfa, delivered via intravenous injection, is a novel bi-functional fusion protein that is composed of an antibody fused with a receptor. Chemotherapy aims to kill cancer cells by directly attacking them, whereas bintrafusp alfa works twofold by preventing cancer from being resistant to a patient’s immune system and stopping cancer cells from growing.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts